This multicenter, randomized, controlled, phase III study is conducted to evaluate the efficacy and safety of first line mCapOX plus Cetuximab versus mFOLFOX6 plus Cetuximab for RAS/BRAF wild-type, MSS, Unresectable Left-Sided mCRC.
Able to provide written informed consent and can understand and comply with the requirements of the study.
Men and women ≥ 18 years of age.
Patients with histologically or cytologically confirmed RAS and BRAF wild-type, MSS/pMMR, metastatic left-sided colorectal adenocarcinoma.
Presence of at least one evaluable lesion, as defined in RECIST Version 1.1.
Patients with mCRC who were initially resectable with R0 resection or radiofrequency or SBRT were excluded.
Patients diagnosed with MSI-H or dMMR by PCR or immunohistochemistry
Hypersensitivity to any therapeutic agent.
Patients who received adjuvant chemotherapy containing oxaliplatin and fluorouracil within 12 months before entering the study.
Meng Qiu
Lead sponsor
West China Hospital
Sponsor institution